+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Middle East & Africa Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Inhibitors Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4771707
  • Report
  • April 2019
  • Region: Middle East, Africa
  • 90 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Eli Lilly
  • Janssen Pharmaceuticals
  • MORE
Market Overview
  • The sodium-dependent glucose co-transporter 2 (SGLT 2) inhibitors market is expected to witness tremendous growth during the forecast period (2019 – 2024), with a CAGR of 17.7%, mainly due to the drugs Jardiance and Farxiga/Forxiga.
  • Jardiance is a once-daily oral medication that is used to control blood glucose levels in people suffering from type-2 diabetes.
  • Patients prefer this drug, as it has a lesser risk of cardiovascular diseases, when compared to other SGLT 2 class of drugs. The countries covered under the Middle East & Africa in the current report are South Africa, Egypt, Oman, Saudi Arabia, and Iran.
Scope of the Report

The Middle East & Africa sodium-dependent glucose co-transporter 2 (SGLT 2) inhibitors market is segmented by drug (Invokana, Jardiance, and Farxiga/Forxiga) and geography.

Key Market Trends

Increasing Diabetic Population is Supporting the SGLT 2 Inhibitors Market to Grow in the Middle East & Africa Region
  • In Middle East & Africa, 15.60 million patients suffer from diabetes, and it is expected to increase in the future, with a CAGR of 4.45% during 2019-2024.
  • According to the IDF, this increase is due to a range of factors that include rapid economic development and urbanization.
  • In 2018, there were 41.6 million patients with obesity in the Middle East and African region. Changes in lifestyle have led to reduced levels of physical activity, increased intake of refined carbohydrates, and a rise in obesity.
Saudi Arabia Holds the Highest Market Share in the Middle East & Africa Region
  • Saudi Arabia held 35% of the market share in the Middle East & Africa Region, with a revenue of USD 44.8 million in 2018.
  • Saudi Arabia had the highest diabetes patient pool, next to Egypt, with 4.37 million patients in 2018.
  • According to the IDF, the most significant expenditures were observed in Saudi Arabia, Iran, and Egypt, with USD 13.1 billion, USD 8.6 billion, and USD 7.9 billion, respectively.
Competitive Landscape
  • The SGLT 2 inhibitors market is highly consolidated, with a few significant manufacturers having a global market presence.
  • The joint ventures that occurred between players in the recent past have helped the companies to strengthen their market presence. For example, Eli Lilly and Boehringer Ingelheim manufacture Jardiance together, which is a popular SGLT 2 class drug.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Eli Lilly
  • Janssen Pharmaceuticals
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Inhibitor (Value and Volume, 2012-2024)
5.1.1.1 Invokana (Canagliflozin)
5.1.1.2 Jardiance (Empagliflozin)
5.1.1.3 Farxiga/Forxiga (Dapagliflozin)
5.2 Geography
5.2.1 Middle East & Africa (Value and Volume, 2012-2024)
5.2.1.1 Saudi Arabia
5.2.1.1.1 By Drug (Invokana (Canagliflozin), Jardiance (Empagliflozin), and Farxiga/Forxiga (Dapagliflozin))
5.2.1.2 Iran
5.2.1.2.1 By Drug (Invokana (Canagliflozin), Jardiance (Empagliflozin), and Farxiga/Forxiga (Dapagliflozin))
5.2.1.3 Egypt
5.2.1.3.1 By Drug (Invokana (Canagliflozin), Jardiance (Empagliflozin), and Farxiga/Forxiga (Dapagliflozin))
5.2.1.4 Oman
5.2.1.4.1 By Drug (Invokana (Canagliflozin), Jardiance (Empagliflozin), and Farxiga/Forxiga (Dapagliflozin))
5.2.1.5 South Africa
5.2.1.5.1 By Drug (Invokana (Canagliflozin), Jardiance (Empagliflozin), and Farxiga/Forxiga (Dapagliflozin))
5.2.1.6 Rest of Middle & Africa
5.2.1.6.1 By Drug (Invokana (Canagliflozin), Jardiance (Empagliflozin), and Farxiga/Forxiga (Dapagliflozin))

6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Eli Lilly
7.1.2 Janssen Pharmaceuticals
7.1.3 Boehringer Ingelheim
7.1.4 AstraZeneca
7.1.5 Bristol Myers Squibb
7.2 MARKET SHARE ANALYSIS
7.2.1 Eli Lilly
7.2.2 Janssen Pharmaceuticals
7.2.3 Boehringer Ingelheim
7.2.4 AstraZeneca
7.2.5 Other Companies

8 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Eli Lilly
  • Janssen Pharmaceuticals
  • Boehringer Ingelheim
  • AstraZeneca
  • Bristol Myers Squibb
Note: Product cover images may vary from those shown
Adroll
adroll